United-Guardian's rally reflects stronger sales, distribution expansion and recovering cosmetic demand, but valuation and trade risks may limit its near-term appeal.
UG reports higher y/y earnings and sales in Q1, driven by strong demand for Renacidin and increased purchases of cosmetic ingredients.
United-Guardian, Inc. (UG) Shareholder/Analyst Call Transcript
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TPL Todd P. Lowe Parthenon LLC | 50,636 | $827,896.96 | $370,655.52 | -$457,241.44 | -55.23% |
Teton Advisors LLC Teton Advisors LLC | 53,761 | $422,524.14 | $405,368.69 | -$17,155.45 | -4.06% |
| Household Products Industry | Consumer Staples Sector | Donna Vigilante CEO | NASDAQ (NMS) Exchange | 910571108 CUSIP |
| US Country | 24 Employees | 9 Feb 2026 Last Dividend | 12 Sep 1985 Last Split | 17 Mar 1992 IPO Date |
United-Guardian, Inc. is a multifaceted corporation that delves into the manufacturing and marketing of a diverse range of products spanning from cosmetic ingredients and pharmaceuticals to medical lubricants and unique industrial products. With its foundation laid in 1942, the company has established its foothold not only within the United States but also on an international scale. Based in Hauppauge, New York, United-Guardian, Inc. has carved a niche for itself in various industries by offering innovative products that cater to the needs of its varied clientele. With a strong emphasis on research and development, the company has continued to evolve and expand its product offerings, meeting the ever-changing demands of the markets it serves. Leveraging the strength of its extensive distribution network, including marketing partners, distributors, and wholesalers, United-Guardian ensures the widespread availability and accessibility of its high-quality products to its customers globally.